BioCardia Announces Japan PMDA Record Of Advice Supports Regulatory Submission For Approval Of CardiAMP Cell Therapy For Ischemic Heart Failure
Rhea-AI Summary
BioCardia (Nasdaq: BCDA) reported that Japan’s PMDA Consultation Record supports a regulatory submission in Q4 2026 for CardiAMP cell therapy to treat ischemic heart failure with reduced ejection fraction. Alignment was reached on remaining questions, post‑marketing study plans, and collaboration with Japanese academic societies for proper-use guidelines.
About 20,000 of 300,000 Japanese patients may initially qualify. BioCardia targets a seven‑month timeline to file through a Designated Marketing Authorization Holder and is ISO13485 compliant, already manufacturing FDA‑cleared cardiovascular products.
Positive
- PMDA Consultation Record supports regulatory submission for CardiAMP therapy in ischemic HFrEF
- Three completed clinical trials form the basis of the CardiAMP submission package
- Estimated 20,000 Japanese patients initially eligible, indicating a defined target population
- Submission timeline guided at seven months, providing a clear regulatory milestone
- Planned use of a Designated Marketing Authorization Holder to initiate commercialization in Japan
- Company is ISO13485 compliant and already manufactures FDA‑cleared cardiovascular devices
Negative
- PMDA review process described as rigorous, implying demanding evidentiary requirements
- PMDA requests detailed confirmation of GDMT use and non‑eligibility for revascularization
- Additional case‑level data required for deaths, transplants, and LVAD implantations
- Post‑marketing studies, training, proctoring, and surveillance add ongoing obligations and costs
News Market Reaction – BCDA
In the May 28 session, BCDA gained 1.83%, reflecting a mild positive market reaction. Argus tracked a peak move of +4.0% during that session. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 21 | CMI trial data | Positive | -0.9% | Preliminary CardiAMP CMI data showed durable exercise gains and less angina. |
| May 19 | Investor conference | Neutral | +5.6% | Announcement of participation in an A.G.P. Healthcare Showcase fireside chat. |
| May 15 | Q1 2026 earnings | Negative | -7.3% | Q1 report with narrower net loss but weakening cash and equity position. |
| May 11 | Earnings call notice | Neutral | +0.9% | Scheduling of Q1 2026 financial results and corporate update call. |
| May 8 | FDA Helix alignment | Positive | +1.8% | FDA agreement on Helix clearance pathways and safety/compatibility comfort. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive clinical and regulatory updates have not consistently translated into sustained upside; one notable divergence saw shares fall on favorable CardiAMP data.
Over the last few weeks, BioCardia reported multiple regulatory and clinical milestones. On May 8, FDA alignment on Helix delivery pathways was followed by modest gains. Q1 2026 results on May 15 showed a narrower net loss but a weaker balance sheet and the stock declined. Subsequent CardiAMP CMI data at EuroPCR on May 21 also saw a small pullback. Today’s PMDA Record of Advice further advances CardiAMP heart failure regulatory progress in Japan, extending this sequence of regulatory steps.
Key Terms
pharmaceutical and medical device agency regulatory
pmda regulatory
ischemic heart failure of reduced ejection fraction medical
hfreF medical
ntprobnp medical
guideline directed medical therapy medical
left ventricular assist device medical
designated marketing authorization holder regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Submission Anticipated in Q4 2026
SUNNYVALE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported the Consultation Record from Japan’s Pharmaceutical and Medical Device Agency (PMDA) supports submission for regulatory approval of the CardiAMP® cell therapy for the treatment of ischemic heart failure of reduced ejection fraction (HFrEF) based on the Company’s three completed clinical trials of this therapy in HFrEF.
PMDA’s Consultation Record confirms alignment on remaining questions to address before, and as part of the submission, for regulatory approval for ischemic HFrEF patients with elevated biomarkers of heart stress (NTproBNP) on stable guideline directed medical therapy (GDMT). PMDA noted that the positive outcomes seen in the trial were credible. It is estimated that 20,000 of the 300,000 patients in Japan would initially be eligible for this therapy. PMDA requested BioCardia demonstrate that enrolled patients were on GDMT and not eligible for revascularization procedures, required per CardiAMP HF protocol, and provide additional details for each incidence of all-cause death, heart transplantation or left ventricular assist device implantation.
“PMDA’s recognition of the urgent unmet clinical need in HFrEF and their support of this novel therapy is valued,” said BioCardia Chief Executive Dr. Peter Altman. “We believe the clinical package prepared for this submission will be sufficient to support approval.”
As part of the submission review for approval of CardiAMP Cell Therapy, the Agency requests post-marketing study plans including the criteria for patient selection, the clinical decision-making framework, and appropriate medical infrastructure and specialist involvement. BioCardia has been guided to collaborate with relevant Japanese academic societies to establish proper-use guidelines and sufficiently consider product training, proctoring, and post market surveillance.
BioCardia’s timeline for PMDA submission is seven months. BioCardia plans to submit with a Designated Marketing Authorization Holder as the optimal pathway for regulatory submission, regulatory review, and to initiate commercialization of the CardiAMP Cell Therapy System while conducting the post market study in Japan. The PMDA review process will be rigorous, and BioCardia believes the documentation to support review is in good shape. BioCardia is ISO13485 compliant for the design, manufacture, and distribution of medical devices for cardiovascular procedures, including catheters for use in delivery of therapeutic agents directly to the heart, and currently manufactures FDA cleared products. When PMDA concludes its technical assessment and recommends approval, the Ministry of Health, Labour and Welfare (MHLW) ultimately issues the certificate enabling commercialization.
About CardiAMP Autologous Cell Therapy
Granted FDA Breakthrough designation, CardiAMP Cell Therapy uses a patient’s own bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure intended to increase capillary density and reduce tissue fibrosis of myocardial tissue to address microvascular dysfunction. Clinical development of the CardiAMP Cell Therapy for heart failure is supported by the Maryland Stem Cell Research Fund and is reimbursed by Centers for Medicare and Medicaid Services (CMS). CAUTION - Limited by United States law to investigational use.
About BioCardia®
BioCardia, Inc., headquartered in Sunnyvale, California, is a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP® autologous and CardiALLO™ allogeneic cell therapies are the Company’s biotherapeutic platforms with three cardiac clinical stage product candidates in development. These therapies are enabled by its Helix™ biotherapeutic delivery and Morph® vascular navigation product platforms, and soon the Heart3D™ fusion imaging platform. BioCardia selectively partners on biotherapeutic delivery with peers developing important biologic therapies. For more information visit www.biocardia.com.
Forward Looking Statements:
This press release contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements include, among other things, statements relating to submission for and subsequent market clearance of CardiAMP Cell Therapy by PMDA. These forward-looking statements are made as of the date of this press release.
We may use terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from the forward-looking statements contained in this press release. Factors that could cause or contribute to such differences include, but are not limited to, the Company’s liquidity position and its ability to raise additional funds, as well as the Company’s ability to successfully progress its clinical trials. As a result of these factors, we cannot assure you that the forward-looking statements in this press release will prove to be accurate. Additional factors that could materially affect actual results can be found in BioCardia’s Form 10-K filed with the Securities and Exchange Commission on March 24, 2026, under the caption titled “Risk Factors” and in its subsequently filed Quarterly Reports on Form 10-Q. BioCardia expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.
Media Contact:
Miranda Peto, Marketing / Investor Relations
Email: mpeto@BioCardia.com
Phone: 650-226-0120
Investor Contact:
David McClung, Chief Financial Officer
Email: investors@BioCardia.com
Phone: 650-226-0120
